CrushSCI.com
107Average days
102.5Median days
54Fastest days
263Longest days
1892025 publications

Paper Review Records

All Paper Review Records

18 valid samples · Newest publication first
Review days = acceptance date − received date. PDF, DOI, and publisher-page sources are retained.

54 days

Generative AI-Designed Immunoglobulin Domain Antibodies (IgDAbs) Against the Fusion Protein as a Neutralizing Agent for Respiratory Syncytial Virus

Authors
Yenisetti Rajendra Prasad; Prakash Y. Khandave; Mihir Ratnaparkhe; Akash G. Kendre; Prasad V. Bharatam; Abhay H. PandeShow moreShow less
Affiliations
1. Department of Biotechnology, National Institute of Pharmaceutical Education and Research (NIPER), S.A.S Nagar (Mohali), India; 2. Department of Pharmacoinformatics, National Institute of Pharmaceutical Education and Research (NIPER), S.A.S Nagar (Mohali), India; 3. Department of Medicinal Chemistry, National Institute of Pharmaceutical Education and Research (NIPER), S.A.S Nagar (Mohali), IndiaShow moreShow less
Source PDF DOI Publisher page
123 days

Identity Testing of Biopharmaceuticals using Nano-Differential-Scanning-Fluorimetry

Authors
Elisabeth Fakler; Steffen Kiessig; Hanns-Christian Mahler; Andrea AllmendingerShow moreShow less
Affiliations
1. ten23 health AG, Basel, Switzerland; 2. Department of Pharmaceutics, Institute of Pharmaceutical Sciences, University of Freiburg, Freiburg i. Br., GermanyShow moreShow less
Source PDF DOI Publisher page
62 days

Effects of Solvation and Noncovalent Interaction on Stabilizing the Molecular Structure of Etoricoxib

Authors
Anna A. Mololina; Konstantin V. Belov; Michael A. Krestyaninov; Hongxun Hao; Ilya A. KhodovShow moreShow less
Affiliations
1. G.A. Krestov Institute of Solution Chemistry, Russian Academy of Sciences, Ivanovo, Russia; 2. National Engineering Research Center of Industrial Crystallization Technology, School of Chemical Engineering and Technology, Tianjin University, Tianjin, China; 3. N.N. Semenov Federal Research Center for Chemical Physics, Russian Academy of Sciences, Moscow, RussiaShow moreShow less
Source PDF DOI Publisher page
100 days

Formulation Development and Characterization of Ibrutinib-Loaded Liposomes with Molecular Dynamics Insights

Authors
Xiufang Cheng; Rijo John; Jasmin Monpara; Pardeep GuptaShow moreShow less
Affiliations
1. Department of Pharmaceutical Sciences, Philadelphia College of Pharmacy, Saint Joseph’s University, Philadelphia, USAShow moreShow less
Source PDF DOI Publisher page
144 days

Effect of Oral Creatine Supplementation on Plasma, Central, and Peripheral Creatine Levels in Creatine Transporter Deficiency Mice

Authors
Naoto Tashiro; Ayaka Miyano; Mizuki Uchi; Tatsuki Uemura; Shingo Ito; Shoma Chikamatsu; Michihiko Sugimoto; Kimi Araki; Satohiro Nakao; Naomi Nakagata; Toru Takeo; Sumio OhtsukiShow moreShow less
Affiliations
1. Department of Pharmaceutical Microbiology, Graduate School of Pharmaceutical Sciences, Kumamoto University, Kumamoto, Japan; 2. Department of Pharmaceutical Microbiology, School of Pharmacy, Kumamoto University, Kumamoto, Japan; 3. Department of Pharmaceutical Microbiology, Faculty of Life Sciences, Kumamoto University, Kumamoto, Japan; 4. Division of Developmental Genetics, Institute of Resource Development and Analysis, Kumamoto University, Kumamoto, Japan; 5. Department of Genetics, School of Medicine, Hyogo Medical University, Hyogo, Japan; 6. Center for Metabolic Regulation of Healthy Aging, Faculty of Life Sciences, Kumamoto University, Kumamoto, Japan; 7. Division of Reproductive Engineering, Center for Animal Resources and Development, Kumamoto University, Kumamoto, Japan; 8. Division of Reproductive Biotechnology and Innovation, Center for Animal Resources and Development, Kumamoto University, Kumamoto, JapanShow moreShow less
Source PDF DOI Publisher page
74 days

Time-Lapse Macro Imaging and LLM-Assisted Phenotypic Analysis of Release Dynamics in Nifedipine Controlled-Release Tablets

Authors
Ke Xu; Yixiang Yang; Yuling Chen; Xinzi Zhang; Yao Fu; Li DengShow moreShow less
Affiliations
1. Key Laboratory of Drug-Targeting and Drug Delivery System of the Education Ministry and Sichuan Province, Sichuan Engineering Laboratory for Plant-Sourced Drug, West China School of Pharmacy, Sichuan University, Chengdu, ChinaShow moreShow less
Source PDF DOI Publisher page

FAQ

How long does PHARMACEUTICAL RESEARCH take to review a manuscript?

As of 2026-11-19, CrushSCI has 18 complete review records for PHARMACEUTICAL RESEARCH. The fastest paper went from submission to acceptance in 54 days (Generative AI-Designed Immunoglobulin Domain Antibodies (IgDAbs) Against the Fusion Protein as a Neutralizing Agent for Respiratory Syncytial Virus, received 2026-08-17, accepted 2026-10-10); the slowest took 263 days. The average is 107 days and the median is 102.5 days.

Expert Matching · Case Demo

Turn Your Submission Goalsinto a Verifiable Journal Plan

Share your field, deadline, and author profile. CrushSCI uses real review records to suggest a title direction, shortlist journals, and estimate timelines.

We will reply within 30 minutes.

CrushSCI online

Client

I work in environmental engineering and need an SCI paper published within three months. I have no grant funding or prominent co-author. Which journals could I target?

CrushSCI

Yes. We will first screen for feasibility against the 90-day deadline, then identify comparable papers without grant support or prominent co-authors. The final shortlist will prioritize research quality and journal scope.

Suggested title
Machine Learning and Life-Cycle Assessment for Predicting and Optimizing Carbon Emissions in Urban Wastewater Treatment

SampleLatest 5 valid paper samples from 2026

Average review59.6 days

Median65 days

Contact CrushSCI

Contact CrushSCI

Leave your email address to discuss academic polishing, structural refinement, or one-to-one guidance.

We will reply within 30 minutes.

Selected service: Academic Consulting Service

Leave your email address

Or email us directly at leader@crushsci.com

Enter your email address so we can reply. Your details will remain private.